Abortion providers' experiences and views on self-managed medication abortion: an exploratory study



      Data on the practice of self-managed medication abortion are limited, in part because this practice takes place purposefully outside of established healthcare systems. Given this, we aimed to ascertain abortion providers' familiarity with self-managed medication abortion and associated complications, compare regional differences and evaluate provider attitudes.

      Study design

      We distributed an online survey to members of Society for Family Planning, Association of Reproductive Health Providers and the Abortion Care Network between July and September 2017 querying experiences with and opinions about self-managed abortion.


      Of 650 respondents, 359 (55.1%) were direct abortion providers. Two hundred and thirty of 335 providers (68.6%) had experience with women trying to interrupt pregnancies on their own, and of those, 153 (76.1%) had seen use of misoprostol and/or mifepristone, and 204 of 342 (59.6%) thought this practice increased in the past 5 years. One hundred and seventeen of 335 (34.9%), witnessed complications from self-managed abortion with misoprostol/mifepristone, most commonly incomplete abortion and less often hemorrhage, sepsis and uterine rupture. Half of providers, 171 of 321 (53.3%), think that the use of misoprostol/mifepristone for the self-management of abortion is safe.


      Two thirds of respondents had experiences with women attempting to self-manage abortion, and about a third witnessed complications related to self-managed medication abortion. About half of respondents agreed that self-managed abortion is safe.


      This study establishes that self-managed abortion is a practice which a majority of respondents have seen among their patients and, because of its prevalence, an area that warrants further research.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Contraception
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Grossman D.
        • Grindlay K.
        Safety of medical abortion provided through telemedicine compared with in person.
        Obstet Gynecol. 2017; 130: 778-782
        • Aiken A.R.A.
        • Digol I.
        • Trussell J.
        • Gomperts R.
        Self reported outcomes and adverse events after medical abortion through online telemedicine: population based study in the Republic of Ireland and Northern Ireland.
        BMJ. 2017; 357j2011
        • Nash E.
        • Gold R.B.
        • Mohammed L.
        • Ansari-Thomas Z.
        • Cappello O.
        Policy trends in the states, 2017.
        Policy Analysis Guttmacher Institute, 2018
        • Bearak J.M.
        • Burke K.L.
        • Jones R.K.
        Disparities and change over time in distance women would need to travel to have an abortion in the USA: a spatial analysis.
        Lancet Public Health. 2017; 2: e493-e500
        • Murtagh C.
        • Wells E.
        • Raymond E.G.
        • Coeytaux F.
        • Winikoff B.
        Exploring the feasibility of obtaining mifepristone and misoprostol from the internet.
        Contraception. 2017; 97: 287-291
        • Kapp N.
        • Blanchard K.
        • Coast E.
        • Ganatra B.
        • Harries J.
        • Footman K.
        • et al.
        Developing a forward-looking agenda and methodologies for research of self-use of medical abortion.
        Contraception. 2018; 97: 184-188
        • Grossman D.
        • Ralph L.
        • Raifman S.
        • Upadhyay U.
        • Gerdts C.
        • Biggs A.
        • et al.
        Lifetime prevalence of self-induced abortion among a nationally representative sample of U.S. women.
        Contraception. 2018; 97: 460
        • Jones R.K.
        How commonly do US abortion patients report attempts to self-induce?.
        Am J Obstet Gynecol. 2011; 204: 23 e1-4
        • Bracken H.
        • Clark W.
        • Lichtenberg E.S.
        • Schweikert S.
        • Tanenhaus J.
        • Barajas A.
        • et al.
        Alternatives to routine ultrasound for eligibility assessment prior to early termination of pregnancy with mifepristone-misoprostol.
        BJOG. 2011; 118: 17-23
        • Hyland P.
        • Raymond E.G.
        • Chong E.
        A direct-to-patient telemedicine abortion service in Australia: retrospective analysis of the first 18 months.
        Aust N Z J Obstet Gynaecol. 2018; 58: 335-340
      1. Medication abortion. State laws and policies: Guttmacher Institute, 2018